Valuation: Spatializer Audio Laboratories, Inc.

Market Cap 6.37M 5.72M 5.22M 4.77M 8.99M 599M 9.27M 62.97M 25.11M 320M 23.92M 23.41M 1.01B P/E 2024
-0.28x
P/E 2025 -0.1x
Enterprise Value 1.7M 1.52M 1.39M 1.27M 2.39M 159M 2.47M 16.76M 6.68M 85.08M 6.37M 6.23M 269M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -

Financials

2024 2025
Net sales - -
Net income -9.57M -8.59M -7.85M -7.16M -13.5M -900M -13.92M -94.6M -37.72M -480M -35.94M -35.17M -1.52B -8.77M -7.87M -7.19M -6.56M -12.37M -825M -12.76M -86.67M -34.56M -440M -32.93M -32.22M -1.39B
Net Debt -2.24M -2.01M -1.84M -1.68M -3.16M -211M -3.26M -22.14M -8.83M -112M -8.41M -8.23M -355M -4.68M -4.2M -3.83M -3.5M -6.59M -440M -6.8M -46.21M -18.43M -235M -17.56M -17.18M -741M
Logo Spatializer Audio Laboratories, Inc.
Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from cannabinoids and taps into its global network of scientists and oncology physicians. The Company is advancing its pipeline of new-generation of naturally occurring and synthetic compounds. It is developing product candidates that target skin-related ailments common among cancer patients, including radiodermatitis, pruritus, rashes and dry skin, as well as indications such as chemotherapy-induced peripheral neuropathy, with future areas of focus that may include depression, pain and anxiety.
Employees
-
Sector
-